[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"weight-loss-maintenance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:weight-loss-maintenance":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,71,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100634146","scalable-behavioral-program-for-weight-loss-maintenance-after-glp-1-and-anti-obesity-medication-discontinuation-100634146",false,"NCT07535892","Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation","Pilot Trial of a Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation","Inclusion Criteria:\n\n* Age 18 years or older\n* Loss of ≥15% of initial body weight using anti-obesity medication\n* Discontinued anti-obesity medication within the past 4 weeks or planning to discontinue prior to randomization\n* ≤3 kg weight regain within the past 3 months\n* Willing and able to participate in a 6-month behavioral intervention, including a 10-week foundational program\n* Willing to complete study assessments at baseline, 3 months, and 6 months, including required in-person visits\n* Medical clearance for participation in moderate physical activity, dietary modification, and mind-based practices\n* Access to reliable internet for participation in virtual sessions and remote data collection\n* English fluency sufficient to complete study procedures\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Medical conditions that would preclude safe participation in physical activity, dietary changes, or mind-based practices (e.g., unstable cardiovascular disease, uncontrolled hypertension, severe orthopedic limitations, or seizure disorders not medically managed)\n* Active psychiatric conditions that would interfere with participation or safety (e.g., untreated major depression, active substance use disorder, or psychosis)\n* Pregnancy, breastfeeding, or plans to become pregnant during the study period\n* Current participation in another structured weight loss or weight maintenance program\n* Continued use of anti-obesity medication after randomization\n* Plans to initiate medications or treatments that may significantly affect body weight during the study period\n* Inability to attend required study visits or participate in virtual sessions and remote data collection\n* Any condition that, in the opinion of the investigators, would compromise participant safety or study integrity","ALL","18 Years",{"count":19,"type":20},64,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a single-site, pilot randomized factorial trial designed to evaluate the feasibility, acceptability, participant perceptions and preliminary effects of a multi-component behavioral intervention to support weight loss maintenance following discontinuation of GLP-1 and other anti-obesity medications. The intervention includes a standardized 10-week foundational weight loss maintenance program combined with candidate support components, including medically tailored meals, YMCA membership, and a structured mind-based program. Participants will be randomized using a 2 × 2 × 2 factorial design and followed for six months. Findings from this pilot study will inform optimization of a scalable intervention for future clinical trials.",[26,27,28,29],"Weight Loss","GLP - 1","Weight Loss Maintenance","Obesity & Overweight",[26,31,32,33],"GLP-1","Anti-Obesity Medication","weight loss maintenance","NOT_YET_RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-26","ACTUAL",{"date":40,"type":20},"2026-11-01",{"date":42,"type":20},"2029-07-31",{"name":44,"class":45},"University of Alabama at Birmingham","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100635672","phase-4-ai-assisted-multi-domain-lifestyle-versus-tirzepatide-for-weight-loss-maintenance-in-adults-with-type-2-diabetes-aim-maintain-100635672","NCT07555730","AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)","Effect of AI-assisted Multi-domain Lifestyle Intervention Versus Tirzepatide Treatment on Weight Loss Maintenance in Adults With Type 2 Diabetes: a Randomized Clinical Trial.","Inclusion Criteria:\n\n1. Male or female participants aged 18 to 65 years at the time of signing informed consent;\n2. Body Mass Index (BMI) ≥27.0 kg\u002Fm²;\n3. Type 2 diabetes mellitus diagnosed by physicians within the past 5 years prior to screening.\n4. Voluntary participation and provide written informed consent.\n\nExclusion Criteria:\n\n1. History of type 1 diabetes mellitus or other types of diabetes, or treatment with insulin.\n2. History of obesity attributable to endocrine disorders or monogenic mutations.\n3. A self-reported change in body weight ≥5.0% within 3 months prior to the day of screening.\n4. Use of medications or products causing weight changes or affecting weight assessment within 3 months prior to the day of screening;\n5. History of major adverse cardiovascular or cerebrovascular events within 6 months before screening (e.g., angina, myocardial infarction, arrhythmia, stroke, intracranial hemorrhage).\n6. History of acute or chronic pancreatitis, pancreatic injury, or other high-risk factors for pancreatitis.\n7. History of cancers (except for localized basal cell carcinoma, adenocarcinoma in situ of cervix or prostate carcinoma in situ); personal or family history of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia syndrome (MEN2), or history of thyroid nodules (category IV or higher).\n8. History of organ transplantation, congenital or acquired immunodeficiency disorders.\n9. History of schizophrenia or major depressive disorder or other severe psychiatric disorders.\n10. Poorly controlled hypertension at screening (systolic blood pressure (SBP) ≥160 mmHg and\u002For diastolic blood pressure (DBP) ≥100 mmHg despite at least 4 weeks of conventional antihypertensive therapy).\n11. History of clinically significant gastric emptying abnormalities, or history of severe chronic gastrointestinal disease, or history of diabetic gastroparesis, or long-term use of drugs that directly affect gastrointestinal motility, or history of gastrointestinal surgery.\n12. Those who are known to be allergic to any component of GLP-1 receptor agonists drugs, or have more than two allergies, or be allergic to soy, dairy, or similar foods.\n13. Laboratory evaluation at screening meet any of the following criteria:\n\n    * Calcitonin ≥50 pg\u002FmL;\n    * Thyroid stimulating hormone (TSH) \\>6.0 or \\\u003C0.4 mIU\u002FL;\n    * Fasting C-peptide \\\u003C0.81 ng\u002FmL;\n    * Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \\>2.5 × upper limit of normal (ULN) or total bilirubin (TBIL) \\>2.5 × ULN (except Gilbert's syndrome with conjugated bilirubin \\\u003C35%);\n    * Triglycerides ≥5.7 mmol\u002FL;\n    * Serum amylase \\>2.5 × ULN;\n    * eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²\n14. History of uncontrolled and potentially unstable proliferative retinopathy or maculopathy within 1 year prior to screening, or history of diabetic ketoacidosis, diabetic non-ketotic hyperosmolar coma, or severe metabolic disturbances with neurological and psychiatric disorders.\n15. History of clinically significant anemia, or epilepsy, or syncope or cardiac conditions (e.g. cardiac arrest, arrhythmias, atrioventricular block, structural heart disease, torsades de pointes).\n16. Patients with active bacterial, viral, or fungal infections requiring hospitalization or antibiotic treatment.\n17. History of infectious diseases such as human immunodeficiency virus (HIV), syphilis, or active hepatitis.\n18. Female patients who are pregnant, lactating, or planning to become pregnant within the next two years.\n19. Participation in other clinical trial within 3 months before screening or currently enrolled in other clinical trial study.\n20. History of drug abuse or alcohol dependence within 6 months before screening.\n21. Any other reasons that researchers deem to unsuitable for participation in this study.","65 Years",{"count":56,"type":20},400,[58],"PHASE4","This is a randomized controlled trial to compare the effect of AI-assisted multi-domain lifestyle and continued tirzepatide on body weight loss maintenance. The study consists of two phases: a 20-week lead-in phase, during which all participants will receive weekly subcutaneous tirzepatide at the maximum tolerated dose (MTD), followed by a 52-week intervention phase.\n\nParticipants who meet the randomization criteria after the lead-in phase will be randomly assigned to either AI-assisted multi-domain lifestyle intervention or tirzepatide 5 mg",[61,28],"Overweight or Obesity; Type 2 Diabetes","2026-04-21",{"date":64,"type":38},"2026-04-29",{"date":66,"type":20},"2026-04-30",{"date":68,"type":20},"2028-09-30",{"name":70,"class":45},"Huazhong University of Science and Technology",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":46},"100576420","optimizing-an-extended-care-intervention-to-promote-weight-loss-maintenance-100576420","NCT06785064","Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance","OPT-X: OPTimizing an EXtended Care Intervention to Promote Weight Loss Maintenance","OPT-X","Inclusion Criteria:\n\n* Age \\>18 years\n* Body mass index (BMI) \\>30 kg\u002Fm2\n* Has regular access to internet (to access Zoom videoconferencing platform)\n* If indicated during screening, willing to obtain medical clearance for exercise from their healthcare provider prior to enrollment\n\nExclusion Criteria:\n\n* Current or recent (past 6 months) use of prescription weight loss medications\n* Weight loss \\>10 pounds in past 6 months (other than postpartum)\n* Pregnancy or anticipating pregnancy\n* Another household member already participating in the study\n* Participation in another randomized research project\n* Uncontrolled hypertension (blood pressure \\>160\u002F100 mm Hg at screening)\n* Any of the following other medical conditions: myocardial infarction or cerebrovascular accident within the last 6 months; unstable angina within the past 6 months; NYHA Class III or IV congestive heart failure; type 1 diabetes; and chronic lung diseases that limit physical activity\n* Unable to identify potential buddy (i.e., adult friend or family member) for extended care intervention phase\n* Residing \\>50 miles from the university (to attend assessment visits)\n* Planning to relocate out of the area in the next 18 months\n* Does not have internet access\n* Unwilling or unable to do any of the following: give informed consent; read\u002Funderstand English; accept random assignment",true,{"count":81,"type":20},544,[23],"The purpose of this study is to find out what combination of components, if any, offers the best support for keeping weight off after someone loses weight. Long term weight loss maintenance is a challenge for many people who lose weight. There are many strategies, or components, people may use to avoid regain, but investigators do not know if there is a best, or optimal, combination of such components that can be done without adding a lot of cost or other burdens for people.\n\n* The primary goal of this clinical trial is to identify the optimal package that maximizes weight loss maintenance.\n* The study also wants to understand the reasons why these components may work and if certain components help specific sub-groups of people.\n\nParticipants will engage in a 16-week Phase 1 Weight Loss Program. Participants who lose 5% or more of their weight during that program will continue to Phase 2 Extended Care and be randomly assigned to 0, 1, 2, 3, or all of four methods of weight loss maintenance. They will use their assigned package for 12 months. Researchers will compare 16 different possible combinations of components and learn which of the 16 packages offers the best support for keeping weight off.\n\nThe four components participants could be assigned to in Phase 2 are:\n\n1. Reduced Food Variety: Limiting the variety of foods participants eat by having them choose a few high-calorie, low nutrient foods to eat regularly\n2. Home-based Resistance Training: Engaging in exercises that build strength from the comfort of the participant's own home\n3. Buddy Training and Support: Having a friend or \"buddy\" get trained to support the participant\n4. Acceptance and Commitment (ACT) Workshops: Having participants learn skills to handle tough thoughts and feelings about weight control in a healthy way\n\nParticipants will have their weight measured and complete surveys 4 times if they complete both Phase 1 and Phase 2. During Phase 1, participants will attend weekly group sessions and be in touch with a study staff member investigators call a Wellness Coach. During Phase 2, participants will stay in touch with their Wellness Coach, use their assigned package, and answer questions about their experience periodically.",[85,86,26,28],"Obesity Prevention","Weight Change",[33,88,89,90,91,92,93,94,95],"weight loss","weight change","health behavior","reduced food variety","ACT workshop","buddy support","home-based resistance training","weight training","RECRUITING","2026-01-06",{"date":99,"type":38},"2026-01-07",{"date":101,"type":38},"2025-12-02",{"date":103,"type":20},"2029-02-28",{"name":44,"class":45},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":54,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":46},"100607562","time-restricted-eating-for-weight-loss-maintenance-2-100607562","NCT07190170","Time Restricted Eating for WeIght LoSs MainTenance-2","Time Restricted Eating for WeIght LoSs MainTenance-2 (TWIST-2): A Single-site, 2-arm Randomized Clinical Trial in Adults With Recent Weight Loss","TWIST-2","Inclusion Criteria:\n\n* ≥5% non-surgical weight loss in the last 3 mos;\n* current BMI 20.5-45 mg\u002Fkg2;\n* between the ages 25 to 65 years old;\n* own a smartphone or willing to use a smartphone if provided for self-monitoring. For in-person screening, eligible participants will provide signed informed consent and have their temporal eating patterns measured.\n\nExclusion Criteria:\n\n* pregnant, trying to get pregnant or breastfeeding;\n* previous or planned bariatric surgery;\n* previous or current history of eating disorder;\n* ongoing participation in another weight-management research study;\n* continued participation in a weight loss program other than the proposed study;\n* currently on appetite suppressants;\n* currently following intermittent fasting; or skipping meals;\n* eating window \\\u003C11h 59min\u002Fday;\n* perform overnight shift work more than once a week;\n* work that includes travel across one or more time zones;\n* taking medications that affect body weight or would preclude TRE;\n* unable or unwilling to provide informed consent;\n* unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment);\n* unwilling to accept randomization assignment;\n* unable to log at least 2 meals into the smartphone app for 70% (\\~20 days) during of the run-in period;\n* have type 1 or type 2 diabetes, or other conditions that would preclude restricted eating windows;\n* narcolepsy,\n* \\>2.5 kg additional weight loss during run-in phase (weight regain is not an exclusion criteria);\n* is non-English speaking (the mCC app is currently only available in English).","25 Years",{"count":115,"type":20},110,[23],"The TWIST 2.0 Study is a 12-month, 2-arm RCT in adults with recent weight loss. We will examine the efficacy of TRE on weight (Aim 1a) and fat mass (Aim 1b) regain, and describe changes in subjective appetite following a mixed-meal tolerance test (Exploratory).",[26,119,28],"Weight Gain",[121,122,123],"obesity","time-restricted eating","weight-loss maintenance","2025-12-23",{"date":126,"type":38},"2025-12-26",{"date":128,"type":38},"2025-10-01",{"date":130,"type":20},"2028-01-01",{"name":132,"class":45},"NYU Langone Health"]